GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Equity-to-Asset

Oncodesign Precision Medicine (XPAR:ALOPM) Equity-to-Asset : -0.04 (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Oncodesign Precision Medicine's Total Stockholders Equity for the quarter that ended in Dec. 2024 was €-0.43 Mil. Oncodesign Precision Medicine's Total Assets for the quarter that ended in Dec. 2024 was €10.71 Mil. Therefore, Oncodesign Precision Medicine's Equity to Asset Ratio for the quarter that ended in Dec. 2024 was -0.04.

The historical rank and industry rank for Oncodesign Precision Medicine's Equity-to-Asset or its related term are showing as below:

XPAR:ALOPM' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.04   Med: 0.5   Max: 0.64
Current: -0.04

During the past 5 years, the highest Equity to Asset Ratio of Oncodesign Precision Medicine was 0.64. The lowest was -0.04. And the median was 0.50.

XPAR:ALOPM's Equity-to-Asset is ranked worse than
87.18% of 1490 companies
in the Biotechnology industry
Industry Median: 0.68 vs XPAR:ALOPM: -0.04

Oncodesign Precision Medicine Equity-to-Asset Historical Data

The historical data trend for Oncodesign Precision Medicine's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine Equity-to-Asset Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Equity-to-Asset
0.56 0.50 0.64 0.22 -0.04

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Equity-to-Asset Get a 7-Day Free Trial 0.64 0.52 0.22 - -0.04

Competitive Comparison of Oncodesign Precision Medicine's Equity-to-Asset

For the Biotechnology subindustry, Oncodesign Precision Medicine's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oncodesign Precision Medicine's Equity-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Oncodesign Precision Medicine's Equity-to-Asset falls into.


;
;

Oncodesign Precision Medicine Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Oncodesign Precision Medicine's Equity to Asset Ratio for the fiscal year that ended in Dec. 2024 is calculated as

Equity to Asset (A: Dec. 2024 )=Total Stockholders Equity/Total Assets
=-0.429/10.711
=-0.04

Oncodesign Precision Medicine's Equity to Asset Ratio for the quarter that ended in Dec. 2024 is calculated as

Equity to Asset (Q: Dec. 2024 )=Total Stockholders Equity/Total Assets
=-0.429/10.711
=-0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oncodesign Precision Medicine  (XPAR:ALOPM) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.


Oncodesign Precision Medicine Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Oncodesign Precision Medicine Business Description

Traded in Other Exchanges
Address
18 rue Jean Mazen, Dijon, FRA, 21000
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine Headlines

No Headlines